[go: up one dir, main page]

BRPI1014322A2 - Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica. - Google Patents

Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.

Info

Publication number
BRPI1014322A2
BRPI1014322A2 BRPI1014322-0A BRPI1014322A BRPI1014322A2 BR PI1014322 A2 BRPI1014322 A2 BR PI1014322A2 BR PI1014322 A BRPI1014322 A BR PI1014322A BR PI1014322 A2 BRPI1014322 A2 BR PI1014322A2
Authority
BR
Brazil
Prior art keywords
interrupting
preventing
production
combination
pharmaceutical composition
Prior art date
Application number
BRPI1014322-0A
Other languages
English (en)
Inventor
Jean-François Rossignol
J Edward Semple
Original Assignee
Romark Lab Lc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43381033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1014322(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Romark Lab Lc filed Critical Romark Lab Lc
Priority to BR122020003634A priority Critical patent/BR122020003634B8/pt
Publication of BRPI1014322A2 publication Critical patent/BRPI1014322A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10F—INORGANIC SEMICONDUCTOR DEVICES SENSITIVE TO INFRARED RADIATION, LIGHT, ELECTROMAGNETIC RADIATION OF SHORTER WAVELENGTH OR CORPUSCULAR RADIATION
    • H10F55/00—Radiation-sensitive semiconductor devices covered by groups H10F10/00, H10F19/00 or H10F30/00 being structurally associated with electric light sources and electrically or optically coupled thereto
    • H10F55/18—Radiation-sensitive semiconductor devices covered by groups H10F10/00, H10F19/00 or H10F30/00 being structurally associated with electric light sources and electrically or optically coupled thereto wherein the radiation-sensitive semiconductor devices and the electric light source share a common body having dual-functionality of light emission and light detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Composite Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
BRPI1014322-0A 2009-06-26 2010-06-23 Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica. BRPI1014322A2 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020003634A BR122020003634B8 (pt) 2009-06-26 2010-06-23 uso de nitazoxanida, tizoxanida ou sal farmaceuticalmente aceitável do mesmo no tratamento de uma doença semelhante a influenza

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22089109P 2009-06-26 2009-06-26
PCT/US2010/039638 WO2010151577A1 (en) 2009-06-26 2010-06-23 Compounds and methods for treating influenza

Publications (1)

Publication Number Publication Date
BRPI1014322A2 true BRPI1014322A2 (pt) 2015-08-25

Family

ID=43381033

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI1014322-0A BRPI1014322A2 (pt) 2009-06-26 2010-06-23 Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
BR122020003634A BR122020003634B8 (pt) 2009-06-26 2010-06-23 uso de nitazoxanida, tizoxanida ou sal farmaceuticalmente aceitável do mesmo no tratamento de uma doença semelhante a influenza

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020003634A BR122020003634B8 (pt) 2009-06-26 2010-06-23 uso de nitazoxanida, tizoxanida ou sal farmaceuticalmente aceitável do mesmo no tratamento de uma doença semelhante a influenza

Country Status (16)

Country Link
US (6) US9023877B2 (pt)
EP (2) EP3895706A1 (pt)
JP (3) JP5932640B2 (pt)
KR (4) KR20190120436A (pt)
CN (2) CN102480967A (pt)
AP (1) AP2012006064A0 (pt)
AU (2) AU2010264479B2 (pt)
BR (2) BRPI1014322A2 (pt)
CA (3) CA3038405C (pt)
EA (1) EA030679B1 (pt)
ES (1) ES2914949T3 (pt)
HK (1) HK1255283A1 (pt)
MX (2) MX391013B (pt)
PT (1) PT2445349T (pt)
WO (1) WO2010151577A1 (pt)
ZA (1) ZA201200263B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1010547A2 (pt) 2009-05-12 2019-04-09 Romark Laboratories L.C. composto, composição, e, métodos para tratar uma infecção viral, e rhabdovírus
PT2445349T (pt) * 2009-06-26 2022-05-16 Romark Laboratories Lc Compostos e métodos para tratamento da gripe
RU2605745C2 (ru) * 2010-11-01 2016-12-27 Ромарк Лабораториз Эл. Си. Соединения алкилсульфинил-замещенных тиазолидов
AU2016201747B2 (en) * 2011-05-16 2017-06-01 Romark Laboratories, L.C. Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
CN103648282B (zh) * 2011-05-16 2017-02-15 罗马克实验室有限公司 噻唑化物类化合物用于预防和治疗病毒性疾病、癌症和由细胞内感染引起的疾病的用途
CN104436197A (zh) 2011-10-21 2015-03-25 艾伯维公司 至少两种直接作用抗病毒剂的组合产品
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104277012B (zh) * 2013-07-04 2017-04-05 中国人民解放军军事医学科学院毒物药物研究所 替唑尼特氨基羧酸酯，及其在药学中的应用
CN104771398B (zh) * 2014-01-09 2017-01-18 湖南大学 N‑[5‑（2‑硝基乙基）噻唑‑2‑基]苯甲酰胺及其医药用途
WO2016077420A1 (en) 2014-11-11 2016-05-19 Romark Laboratories, L.C. Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof
JP6955648B2 (ja) 2015-09-01 2021-10-27 ファースト ウェーブ バイオ インコーポレイテッド 異常炎症反応に関連する状態を処置するための方法および組成物
US11135202B2 (en) * 2016-03-31 2021-10-05 Romark Laboratories L.C. Thiazolide compounds for treating viral infections
EP3442580B1 (en) 2016-04-11 2020-09-23 Genfit Methods of treatment for cholestatic and fibrotic diseases
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2018195035A1 (en) 2017-04-18 2018-10-25 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase a3
CN107286149B (zh) * 2017-05-10 2021-02-12 南华大学 N-(5-胡椒基噻唑-2-基)哌啶基酰胺及其应用
CN107141267B (zh) * 2017-06-22 2019-04-09 湖南大学 N-(5-酰基噻唑-2-基)酰胺及其制备方法与应用
CN107235927B (zh) * 2017-06-22 2019-04-16 湖南大学 N-(5-酰基噻唑-2-基)哌嗪基酰胺及其医药用途
KR102077833B1 (ko) * 2018-12-10 2020-02-14 류형준 기능성 식품조성물
WO2020227004A1 (en) * 2019-05-03 2020-11-12 President And Fellows Of Harvard College Combination therapy for treating influenza virus infection
WO2021046446A1 (en) * 2019-09-06 2021-03-11 Yourchoice Therapeutics, Inc. Compositions and methods of use for enhancing fertility
CN118978524A (zh) * 2019-09-11 2024-11-19 绍兴君科臻元医药科技有限公司 硝唑尼特衍生物及其医药用途
US20230077704A1 (en) * 2020-01-21 2023-03-16 Academy Of Military Medical Sciences Application of nitazoxanide and active form thereof, tizoxanide, in treatment of sars-cov-2 infection
WO2021180251A1 (zh) * 2020-03-09 2021-09-16 北京强新生物科技有限公司 治疗冠状病毒感染的联用药物及治疗方法
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
RU2726070C1 (ru) * 2020-03-23 2020-07-08 Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ патогенетической коррекции метаболических нарушений при инфекционном мононуклеозе, вызванном вирусом Эпштейна-Барр
WO2021202600A1 (en) * 2020-03-30 2021-10-07 The Scripps Research Institute Small molecule inhibitors of influenza hemagglutinin
JP2023537237A (ja) 2020-07-20 2023-08-31 ロマーク ラボラトリーズ，リミティド カンパニー チゾキサニドおよび２－ヒドロキシ－ｎ－（５－クロロ－１，３－チアゾル－２－イル）ベンズアミド（ｒｍ－４８４８）とエタノールアミン、モルホリン、プロパノールアミン、ピペラジン、およびｎ－メチルピペラジンの結晶塩
CA3189487A1 (en) 2020-08-24 2023-03-03 Jean-Francois Rossignol Use of thiazolides against coronaviruses
WO2022109148A1 (en) * 2020-11-18 2022-05-27 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Small molecule inhibitors of sars-cov-2 infections
CN116456980A (zh) * 2021-03-29 2023-07-18 北京大学 噻唑类化合物在制备治疗和预防癌症药物中的用途
MX2023011950A (es) * 2021-04-10 2024-01-08 Rhein Siegfried Sa De Cv Uso de nitazoxanida para la preparacion de medicamento para prevenir o tratar infeccion causada por coronavirus sars-cov-2.
WO2022218239A1 (zh) * 2021-04-12 2022-10-20 杜心赟 新型噻唑类化合物及其制备方法和用途
CN113277994A (zh) * 2021-05-18 2021-08-20 杜心赟 噻唑类化合物及其制备方法和用途
WO2023198095A1 (zh) * 2022-04-12 2023-10-19 成都贝诺科成生物科技有限公司 一种硝基噻唑衍生物在制备抑制幽门螺杆菌的抑菌剂中的用途

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1177206A (en) 1967-11-28 1970-01-07 Pfizer & Co C Lung Antiviral Factor
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US4343945A (en) * 1979-01-23 1982-08-10 Olin Corporation 5-Benzamido-3-trichloromethyl-1,2,4-thiadiazoles and their use as herbicides, fungicides and insecticides
US4337081A (en) * 1979-01-23 1982-06-29 Olin Corporation 5-Amido-3-trihalomethyl-1,2,4-thiadiazoles and their use as herbicides
SU910628A1 (ru) 1980-04-22 1982-03-07 Гродненский государственный медицинский институт Способ получени 2-ациламинотиазолов
JPS56158703A (en) 1980-05-10 1981-12-07 Sankyo Co Ltd Fungicide
US4416683A (en) * 1980-09-16 1983-11-22 Eli Lilly And Company Benzamides, compositions and agricultural method
JPS649978A (en) 1987-07-02 1989-01-13 Shionogi & Co Perfluoroalkylisoxazole derivative
US4874864A (en) 1988-05-24 1989-10-17 Pfizer Inc. Benzamide protease inhibitors
US5169846A (en) * 1989-10-12 1992-12-08 Crooks Michael J Non-aqueous micellar solutions of anthelmintic benzimidazoles, closantel, or phenothiazine, and insect growth regulators
AU705226B2 (en) 1994-01-28 1999-05-20 University Of Kentucky Research Foundation, The Codrugs as a method of controlled drug delivery
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
DK0755386T3 (da) * 1994-04-13 2002-08-26 Romark Lab Lc Benzamid-derivater, sammensætninger indeholdende nævnte derivat og anvendelse deraf
MX9604483A (es) * 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5968961A (en) * 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
EA002920B1 (ru) 1997-05-07 2002-10-31 Ромарк Лабораториз Л.С. Фармацевтические композиции на основе тизоксанида и нитазоксанида
GB9725298D0 (en) 1997-11-28 1998-01-28 Zeneca Ltd Insecticidal thiazole derivatives
EP1614678B1 (en) 1998-07-08 2014-01-01 Sanofi-Aventis Deutschland GmbH Sulfur substituted sulfonylaminocarboxylic acid N-heteroarylamides, their preparation, their use and pharmaceutical preparations comprising them
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US6849254B1 (en) * 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections
US7229822B1 (en) 2000-02-29 2007-06-12 Univ Columbia Melanoma differentation associated gene-5 and vectors and cells containing same
DK1347971T3 (da) * 2000-12-21 2006-05-15 Bristol Myers Squibb Co Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
ATE315555T1 (de) * 2001-05-11 2006-02-15 Pfizer Prod Inc Thiazolderivate und ihre verwendung als cdk- inhibitoren
WO2002092584A1 (en) 2001-05-14 2002-11-21 Nihon Nohyaku Co., Ltd. Thiadiazole derivatives, pesticides for agricultural and horticultural use and usage thereof
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2003335680A (ja) 2002-05-21 2003-11-25 Otsuka Pharmaceut Factory Inc Ａｃａｔ−１阻害剤
WO2003103648A1 (ja) 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 糖尿病治療薬
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
CA2500468A1 (en) 2002-09-28 2004-04-08 Massachussets Institute Of Technology Influenza therapeutic
US6737382B1 (en) * 2002-10-23 2004-05-18 Nippon Soda Co. Ltd. Insecticidal aminothiazole derivatives
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
JP4432901B2 (ja) * 2003-02-26 2010-03-17 萬有製薬株式会社 ヘテロアリールカルバモイルベンゼン誘導体
WO2004085433A2 (en) 2003-03-28 2004-10-07 Pharmacia & Upjohn Company Llc Positive allosteric modulators of the nicotinic acetylcholine receptor
CA2532313A1 (en) 2003-07-16 2005-01-27 Institute Of Medicinal Molecular Design. Inc. Medicament for treatment of dermal pigmentation
US20050090506A1 (en) * 2003-10-24 2005-04-28 Nippon Soda Co., Ltd. Insecticidal perfluoroalkylthiazole derivatives
US7683097B2 (en) 2004-05-27 2010-03-23 Propharmacon Inc. Topoisomerase inhibitors
UA90864C2 (en) * 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
US20060194853A1 (en) 2004-10-08 2006-08-31 Rossignol Jean F Alkyl benzamides
US8357664B2 (en) * 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
EP1871365A2 (en) * 2005-04-12 2008-01-02 Romark Laboratories, L.C. Methods for treating diseases through inhibition the function of molecular chaperones such as protein disulfide isomerases , pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
BRPI0608910A2 (pt) 2005-05-09 2010-02-17 Achillion Pharmaceuticals Inc uso de um composto da fórmula ou um sal ou hidrato farmaceuticamente aceitável desse, composto ou sal ou hidrato do mesmo, composição farmacêutica e composição farmacêutica embalada
MX2007015216A (es) 2005-06-03 2008-02-22 Xenon Pharmaceuticals Inc Derivados de aminotiazol y sus usos como agentes terapeuticos.
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
CA2613517A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Pyrazole based lxr modulators
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
CA2615890A1 (en) 2005-08-02 2007-02-08 Irm Llc 5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors
NZ569817A (en) 2005-12-21 2011-10-28 Abbott Lab Anti-viral compounds
WO2007081974A2 (en) 2006-01-09 2007-07-19 Romark Laboratories, L.C. Viral hepatitis treatment
WO2007125103A2 (en) 2006-04-28 2007-11-08 Transtech Pharma, Inc. Benzamide glucokinase activators
MX2008015217A (es) 2006-05-31 2008-12-12 Abbott Lab Compuestos de tiazol como ligandos del receptor de canabinoides y usos de los mismos.
CA2654898A1 (en) 2006-07-07 2008-10-01 Boehringer Ingelheim International Gmbh New chemical compounds
WO2008033466A2 (en) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
EP2099300A4 (en) 2006-12-05 2011-12-07 Glaxosmithkline Llc IL-8 RECEPTOR ANTAGONISTS
WO2009001214A2 (en) 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US8124632B2 (en) * 2007-08-03 2012-02-28 Romark Laboratories, L.C. Alkylsulfonyl-substituted thiazolide compounds
WO2009065096A1 (en) 2007-11-16 2009-05-22 University Of Medicine And Dentistry Of New Jersey Mechanism-based small-molecule parasite inhibitors
US20100081713A1 (en) * 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections
US20100009970A1 (en) * 2008-03-19 2010-01-14 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
AU2009257372A1 (en) 2008-06-11 2009-12-17 Irm Llc Compounds and compositions useful for the treatment of malaria
AR073501A1 (es) 2008-09-08 2010-11-10 Boehringer Ingelheim Int Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
EP2346853A2 (en) 2008-11-19 2011-07-27 Schering Corporation Inhibitors of diacylglycerol acyltransferase
US8835644B2 (en) * 2009-03-20 2014-09-16 University Of Virginia Patent Foundation Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials
BRPI1010547A2 (pt) 2009-05-12 2019-04-09 Romark Laboratories L.C. composto, composição, e, métodos para tratar uma infecção viral, e rhabdovírus
PT2445349T (pt) * 2009-06-26 2022-05-16 Romark Laboratories Lc Compostos e métodos para tratamento da gripe

Also Published As

Publication number Publication date
EP2445349A4 (en) 2012-12-05
PT2445349T (pt) 2022-05-16
AU2017221828A1 (en) 2017-09-21
JP2016172749A (ja) 2016-09-29
ZA201200263B (en) 2012-09-26
MX391013B (es) 2025-03-21
CN102480967A (zh) 2012-05-30
JP6464225B2 (ja) 2019-02-06
US9820975B2 (en) 2017-11-21
BR122020003634B1 (pt) 2021-03-16
US20150250768A1 (en) 2015-09-10
EP3895706A1 (en) 2021-10-20
AP2012006064A0 (en) 2012-02-29
MX2012000230A (es) 2012-01-25
US20160228415A1 (en) 2016-08-11
US20180078533A1 (en) 2018-03-22
CN108042535A (zh) 2018-05-18
CA2766642A1 (en) 2010-12-29
US10363243B2 (en) 2019-07-30
ES2914949T3 (es) 2022-06-17
KR20180032689A (ko) 2018-03-30
MX341877B (es) 2016-09-06
EA030679B1 (ru) 2018-09-28
US11850237B2 (en) 2023-12-26
KR20190120436A (ko) 2019-10-23
KR20170141830A (ko) 2017-12-26
US20190307730A1 (en) 2019-10-10
JP5932640B2 (ja) 2016-06-08
EP2445349B1 (en) 2022-02-09
CA2766642C (en) 2017-09-05
AU2010264479B2 (en) 2017-06-01
BR122020003634B8 (pt) 2021-07-27
JP2012531420A (ja) 2012-12-10
WO2010151577A1 (en) 2010-12-29
KR20120102570A (ko) 2012-09-18
EA201270077A1 (ru) 2012-12-28
CA3038405C (en) 2022-02-01
JP6188863B2 (ja) 2017-08-30
US9023877B2 (en) 2015-05-05
US10912768B2 (en) 2021-02-09
KR101812054B1 (ko) 2017-12-27
EP2445349A1 (en) 2012-05-02
US20210177809A1 (en) 2021-06-17
AU2010264479A1 (en) 2012-01-19
US9345690B2 (en) 2016-05-24
CA3038405A1 (en) 2010-12-29
CA2968113A1 (en) 2010-12-29
CA2968113C (en) 2019-05-14
JP2017197552A (ja) 2017-11-02
HK1255283A1 (zh) 2019-08-09
US20100330173A1 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
BRPI1014322A2 (pt) Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
BR112013020425A2 (pt) composições e métodos para o tratamento ou prevenção de infecção por vírus da hepatite b
MD4589B1 (ro) Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
BRPI1007379A2 (pt) composições e métodos para o tratamento ou a prevenção de infecções orais por e. coli
WO2008115281A3 (en) Compounds for treating viral infections
BR112013013435A2 (pt) composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou condição de doença mediados por uma cinase de fgfr, e, processo para a preparação de um composto.
BRPI0807597A2 (pt) Composição farmacêutica, e, método para tratar infecção por vírus da influenza
BR112013011737A2 (pt) composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv
BR112013010738A2 (pt) composto, composição farmacêutica, e, método para tratar uma infecção viral
AP2012006135A0 (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof.
HUE049880T2 (hu) Anyag és eljárások Her-3-mal összefüggõ betegségek kezelésére vagy megelõzésére
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
BRPI1013984A2 (pt) composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
AP2011005901A0 (en) Thienopyridine derivatives for the treatment and prevention of dengue virus infections.
BRPI1013396A2 (pt) composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.
BRPI0716536A2 (pt) produÇço de vacinas de vÍrus influenza, sem a utilizaÇço de ovos
BR112014004181A2 (pt) composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
FI20096050A7 (fi) Menetelmä kalsiumkarbonaatin ja ksylaanin saostamiseksi, menetelmällä valmistettu tuote ja sen käyttö
BRPI0820162A2 (pt) composto, composição farmacêutica, método para a profilazia ou tratamento de infecção pela hiv ou para a profilaxia, tratamento ou retardo no início da aids
IL202450A (en) Pharmaceutical composition to treat influenza virus infection
BRPI0814300A2 (pt) Composto, composição farmacêutica, e, método para tratar uma infecção viral
BRPI0819534A2 (pt) Composição farmacêutica, método para tratar hiv ou aids e método para preparar uma composição farmacêutica, forma de dosagem e composição"
BRPI1014691A2 (pt) Composto, e, processo para a preparação de um composto.
WO2010095041A3 (en) Compositions, methods, and kits for treating influenza viral infections
BR112014025339A8 (pt) método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]